Trade Secret Litigation Trends in Life Sciences

Why It Matters

The rise in trade‑secret suits threatens R&D pipelines and valuation of life‑science firms, making robust IP protection a strategic imperative. Companies that fail to manage confidential information risk costly damages and market setbacks.

Key Takeaways

• DTSA created federal private right for trade secret claims
• ADC market projected to exceed $20 billion by 2033
• Employee poaching fuels misappropriation claims in biotech firms
• Injunctions can force patent reassignment under DTSA rulings

Pulse Analysis

The Defend Trade Secrets Act reshaped the legal landscape for life‑science companies, turning trade‑secret protection from a niche concern into a core risk‑management pillar. By establishing a uniform federal cause of action, the DTSA lowered procedural barriers and encouraged plaintiffs to bring cases in federal courts, where juries have handed down multi‑hundred‑million‑dollar verdicts. This legal certainty has prompted firms to audit confidentiality protocols and embed trade‑secret clauses in employment contracts.

Concurrently, the sector’s scientific evolution fuels the litigation surge. The rapid expansion of biologics, especially antibody‑drug conjugates, has created high‑value, unrevealed data that competitors covet. As M&A activity intensifies, acquiring firms inherit not only patents but also proprietary processes and clinical‑trial insights that remain trade secrets. Employee turnover amplifies the risk: senior scientists moving between rivals carry tacit knowledge that can be weaponized, prompting companies to tighten non‑compete enforcement and exit interview procedures.

Recent case law underscores the stakes. The Insulet v. EOFlow decision affirmed that courts can award both compensatory and exemplary damages, and even mandate reassignment of patents filed using stolen secrets. United Therapeutics and Aptar cases broadened the definition of protectable information to include business models and device designs. These outcomes signal that proactive IP governance—clear collaboration agreements, robust cybersecurity, and vigilant monitoring of former employee activities—is essential to safeguard innovation and preserve shareholder value.